Business
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
DARMSTADT, Germany, July 01, 2025--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions.
About this update from Merck Kgaa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/534833bd58c031df957e75eb3caee431"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bp_ku.DKDKLTHbhKKDvQNQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/534833bd58c031df957e75eb3caee431","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/w_pHWA_HqqEQKZn9xt6WDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/534833bd58c031df957e75eb3caee431","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector","length":141,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Acquisition marks the formation of a rare tumor business for Merck KGaA, Darmstadt, Germany including SpringWorks portfolio and pimicotinib","length":139,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"SpringWorks rare tumor portfolio includes Ogsiveo, a first-in-disease systemic therapy for adults with desmoid tumors and Gomekli a first and only approved therapy for adults and children with NF1-PN","length":199,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":479,"olType":false},{"type":"text","content":"Not intended for UK-based media","length":31,"tagName":"p"},{"type":"text","content":"DARMSTADT, Germany, July 01, 2025--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions.","length":371,"tagName":"p"},{"type":"text","content":"The definitive agreement between Merck KGaA, Darmstadt, Germany and SpringWorks, based in Stamford, Connecticut, was announced on 28 April, 2025. It represents one of the biggest M&A deals in the global biopharma sector so far in 2025. The business combination will immediately contribute to Merck KGaA, ...